Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: Final results of the VICTOR trial

Journal of Clinical Oncology

Volumn 28, Issue 30, 2010, Pages 4575-4580

  Midgley, Rachel S ^a   McConkey, Christopher C ^a   Johnstone, Elaine C ^a   Dunn, Janet A ^a   Smith, Justine L ^a   Grumett, Simon A ^a   Julier, Patrick ^a   Iveson, Claire ^a   Yanagisawa, Yoko ^a   Warren, Bryan ^a   Langman, Michael J ^a   Kerr, David J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; FORMALDEHYDE; PARAFFIN; PLACEBO; ROFECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LACTONE; PTGS2 PROTEIN, HUMAN; SULFONE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DUODENUM ULCER; EPILEPSY; FEMALE; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; HUMAN; IMMUNOHISTOCHEMISTRY; INDIGESTION; INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEURALGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DRUG RECALL; ENZYMOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED KINGDOM;

AGED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LACTONES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SAFETY-BASED DRUG WITHDRAWALS; SULFONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 78049523725     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.6244     Document Type: Article

References (28)

1. Midgley R, Kerr D: Towards post-genomic investigation of colorectal cancer. Lancet 355:669-670, 2000 (Pubitemid 30107617)
2. Gray R, Barnwell J, McConkey C, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007
3. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial - QUASAR Collaborative Group. Lancet 355:1588-1596, 2000
4. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005 (Pubitemid 46211509)
5. Fenwick SW, Toogood GJ, Lodge JP, et al: The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125:716-729, 2003 (Pubitemid 37070690)
6. Oshima M, Murai N, Kargman S, et al: Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61:1733-1740, 2001 (Pubitemid 34292612)
7. Sheehan KM, Sheahan K, O'Donoghue DP, et al: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282:1254-1257, 1999
8. Soumaoro LT, Uetake H, Higuchi T, et al: Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10:8465-8471, 2004 (Pubitemid 40053411)
9. Xiong B, Sun TJ, Hu WD, et al: Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol 11:1105-1108, 2005 (Pubitemid 40352994)
10. Haile RW, Yochim JM, Cortessis VK, et al: A molecular/epidemiologic analysis of expression of cyclooxygenases 1 and 2, use of nonsteroidal anti-inflammatory drugs, and risk of colorectal adenoma. Clin Colorectal Cancer 4:390-395, 2005 (Pubitemid 41268776)
11. Chan AT, Ogino S, Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142, 2007 (Pubitemid 47010839)
12. Arber N, Eagle CJ, Spicak J, et al: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895, 2006 (Pubitemid 44315981)
13. Baigent C, Patrono C: Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal. Arthritis Rheum 48:12-20, 2003 (Pubitemid 36091643)
14. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899, 2003 (Pubitemid 36297997)
15. Bertagnolli MM, Eagle CJ, Zauber AG, et al: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884, 2006 (Pubitemid 44315980)
16. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102, 2005 (Pubitemid 40365350)
17. Hallak A, Alon-Baron L, Shamir R, et al: Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 48:1998-2002, 2003
18. Langman MJ, Jensen DM, Watson DJ, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929-1933, 1999
19. Kerr DJ, Dunn JA, Langman MJ, et al: Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357:360-369, 2007 (Pubitemid 47124136)
20. Altman DG: Practical Statistics for Medical Research. London, United Kingdom, Chapman and Hall, 1991, pp 443-445
21. Mahesh K, Parmar B, Machin D: Survival Analysis: A Practical Approach. New York, NY, John Wiley & Sons, 2005
22. Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 369:1603-1613, 2007 (Pubitemid 46710123)
23. O'Connell MJ, Campbell ME, Goldberg RM, et al: Survival following recurrence in stage II and III colon cancer: Findings from the ACCENT data set. J Clin Oncol 26:2336-2341, 2008
24. Edelman MJ, Watson D, Wang X, et al: Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26:848-855, 2008 (Pubitemid 351398075)
25. Khor LY, Bae K, Pollack A, et al: COX-2 expression predicts prostate-cancer outcome: Analysis of data from the RTOG 92-02 trial. Lancet Oncol 8:912-920, 2007 (Pubitemid 47495777)
26. Pantaleo MA, Astolfi A, Nannini M, et al: Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 99:1729-1734, 2008
27. Kearney PM, Baigent C, Godwin J, et al: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332:1302-1308, 2006
28. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080, 2005 (Pubitemid 40365348)